Light Therapy in Parkinson's Disease
Light Therapy in Parkinson's Disease : Effect on Motor Symptoms, Sleep, Circadian Rhythms, and Mood
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Patrice BOURGIN, MD
- Phone Number: 0033 03.88.11 67.73.
- Email: pbourgin@unistra.fr
Study Locations
-
-
-
Strasbourg, France, 67000
- University Hospital, Strasbourg, France
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Idiopathic Parkison's Disease, low or moderately severe
- Hoehn&Yahr <4
- 4 to < 15 years of evolution·
- Between 45-75 years old
- Absence of dementia : MMSE > 23·
- No severe depression
- Stable medication levels during the 5 weeks before inclusion
Exclusion Criteria:
- Secondary or severe Parkinson's disease
- Ocular pathologies (i.e. retinopathy)
- Photosensitive medication
- Antidepressant treatment·
- Major depression syndrome
- MMSE < 23
- Circadian rhythm problems
- Sleep apnea syndrome
- Manifested or acute psychiatric comorbidities
- Pregnant women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Active light therapy (10,000 lux)
Light therapy: DayVia lamp 10000 lux
|
4 weeks of active light therapy with DayVia lamp 10000 lux
|
|
Placebo Comparator: Placebo light therapy (70 lux)
Placebo light therapy
|
4 weeks with Placebo light therapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Global score :Unified Parkinson's Disease Rating Scale (UPDRS) I II III
Time Frame: 5 weeks
|
5 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Patrice BOURGIN, MD, University Hospital, Strasbourg, France
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 5063
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.